[go: up one dir, main page]

WO2008111669A1 - 糖尿病性神経障害の新規予防剤及び／又は治療剤 - Google Patents

糖尿病性神経障害の新規予防剤及び／又は治療剤 Download PDF

Info

Publication number
WO2008111669A1
WO2008111669A1 PCT/JP2008/054710 JP2008054710W WO2008111669A1 WO 2008111669 A1 WO2008111669 A1 WO 2008111669A1 JP 2008054710 W JP2008054710 W JP 2008054710W WO 2008111669 A1 WO2008111669 A1 WO 2008111669A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic
therapeutic agent
prophylactic
nerve disorder
abnormal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/054710
Other languages
English (en)
French (fr)
Inventor
Toshiaki Aoki
Nobuhito Murai
Seiji Tamura
Hiroko Yamamoto
Nozomu Hamakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009009701A priority Critical patent/MX2009009701A/es
Priority to JP2009504092A priority patent/JP5278308B2/ja
Priority to AU2008225379A priority patent/AU2008225379A1/en
Priority to CA002680938A priority patent/CA2680938A1/en
Priority to CN2008800084866A priority patent/CN101646662B/zh
Priority to EP08722106A priority patent/EP2123643A4/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to BRPI0808806-3A priority patent/BRPI0808806A2/pt
Priority to US12/530,745 priority patent/US20100113451A1/en
Publication of WO2008111669A1 publication Critical patent/WO2008111669A1/ja
Priority to IL200669A priority patent/IL200669A0/en
Anticipated expiration legal-status Critical
Priority to US13/592,544 priority patent/US20130023535A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

　本発明は、式（Ｉ）の２‐［（置換インデン‐７‐イルオキシ）メチル］モルホリン又はその薬学的に許容される塩を有効成分として含有する糖尿病性神経障害の予防剤及び／又は治療剤に関する。本発明は，優れた糖尿病性神経障害の予防剤及び／又は治療剤を提供するものとして有用であり糖尿病性運動神経障害（筋力低下障害（独立歩行不能な筋力低下障害など）など）、糖尿病性感覚神経障害（感覚異常（振動覚異常など）、アロディニア、感覚低下（四肢の痺れ、冷感など）、疼痛など）、糖尿病性自律神経障害（便秘や下痢などの便通異常、排尿機能異常、インポテンス、起立性低血圧症、発汗異常、心拍変動異常、胃内容物排出遅延など）の予防剤及び／又は治療剤を提供するものとして特に有用である。また、本発明は、糖尿病性神経障害の病態改善剤を提供するものとして、特に有用である。
PCT/JP2008/054710 2007-03-15 2008-03-14 糖尿病性神経障害の新規予防剤及び／又は治療剤 Ceased WO2008111669A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0808806-3A BRPI0808806A2 (pt) 2007-03-15 2008-03-14 Agente preventivo e/ou terapêutico para a neuropatia diabética.
JP2009504092A JP5278308B2 (ja) 2007-03-15 2008-03-14 糖尿病性神経障害の新規予防剤及び／又は治療剤
AU2008225379A AU2008225379A1 (en) 2007-03-15 2008-03-14 Novel preventive and/or therapeutic agent for diabetic neuropathy
CA002680938A CA2680938A1 (en) 2007-03-15 2008-03-14 Novel preventive and/or therapeutic agent for diabetic neuropathy
CN2008800084866A CN101646662B (zh) 2007-03-15 2008-03-14 糖尿病性神经障碍的预防剂和/或治疗剂
MX2009009701A MX2009009701A (es) 2007-03-15 2008-03-14 Agente preventivo y/o terapeutico novedoso para neuropatia diabetica.
US12/530,745 US20100113451A1 (en) 2007-03-15 2008-03-14 Novel preventive and/or therapeutic agent for diabetic neuropathy
EP08722106A EP2123643A4 (en) 2007-03-15 2008-03-14 NOVEL PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR TREATING DIABETIC NEUROPATHY
IL200669A IL200669A0 (en) 2007-03-15 2009-09-01 Novel preventive and/or therapeutic agent for diabetic neuropathy
US13/592,544 US20130023535A1 (en) 2007-03-15 2012-08-23 Method of preventing and/or treating diabetic neuropathy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-066727 2007-03-15
JP2007066727 2007-03-15
JP2007-242210 2007-09-19
JP2007242210 2007-09-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/592,544 Division US20130023535A1 (en) 2007-03-15 2012-08-23 Method of preventing and/or treating diabetic neuropathy

Publications (1)

Publication Number Publication Date
WO2008111669A1 true WO2008111669A1 (ja) 2008-09-18

Family

ID=39759597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/054710 Ceased WO2008111669A1 (ja) 2007-03-15 2008-03-14 糖尿病性神経障害の新規予防剤及び／又は治療剤

Country Status (12)

Country Link
US (2) US20100113451A1 (ja)
EP (1) EP2123643A4 (ja)
JP (1) JP5278308B2 (ja)
KR (1) KR20090130052A (ja)
AU (1) AU2008225379A1 (ja)
BR (1) BRPI0808806A2 (ja)
CA (1) CA2680938A1 (ja)
IL (1) IL200669A0 (ja)
MX (1) MX2009009701A (ja)
RU (1) RU2465906C2 (ja)
TW (1) TW200846003A (ja)
WO (1) WO2008111669A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029958A1 (ja) 2008-09-11 2010-03-18 アステラス製薬株式会社 侵害受容性疼痛の新規治療用医薬組成物
WO2010029959A1 (ja) 2008-09-11 2010-03-18 アステラス製薬株式会社 モルホリン誘導体の新規な塩

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2428181C1 (ru) * 2010-05-25 2011-09-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. И.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Способ снижения уровня гликемии и инсулинорезистентности у больных сахарным диабетом 2 типа

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1106184A2 (en) * 1999-12-07 2001-06-13 Pfizer Products Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
JP2002524513A (ja) * 1998-09-15 2002-08-06 イーライ・リリー・アンド・カンパニー 持続痛の治療
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109088A (en) * 1975-01-29 1978-08-22 Yamanouchi Pharmaceutical Co., Ltd. 2-(indenyloxymethyl) morpholine derivatives
JPS52111580A (en) * 1976-03-15 1977-09-19 Yamanouchi Pharmaceut Co Ltd Novel indene derivatives and salts thereof
UA41350C2 (uk) * 1993-02-10 2001-09-17 Яманоуті Фармасьютікал Ко., Лтд. Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
CN1984681A (zh) * 2004-07-14 2007-06-20 安斯泰来制药株式会社 中枢神经疾病发病后的功能障碍恢复促进剂
AU2007256352A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002524513A (ja) * 1998-09-15 2002-08-06 イーライ・リリー・アンド・カンパニー 持続痛の治療
EP1106184A2 (en) * 1999-12-07 2001-06-13 Pfizer Products Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAMERON ET AL., THE JOURNAL OF EXPERIMENTAL PHYSIOLOGY, vol. 74, 1989, pages 917 - 926
KOJIMA T. ET AL.: "Synthesis of (plus or minus)-2-[(Inden-7-yloxy)methyl]morpholine Hydrochloride (YM-08054, Indeloxazine Hydrochloride) and Its Derivatives with Potential Cerebral-Activating and Antidepressive Properties", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 33, no. 9, 1985, pages 3766 - 3774, XP008112250 *
MURAKAWA K.: "Ko Utsu Yaku", PAIN CLINICIANS, vol. 16, no. 6, 1995, pages 814 - 819, XP003021977 *
OTSUKA M. ET AL.: "Ko Utsu Yaku no Chintsu", PAIN CLINICIANS, vol. 22, no. 10, 2001, pages 1431 - 1436, XP003021976 *
See also references of EP2123643A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029958A1 (ja) 2008-09-11 2010-03-18 アステラス製薬株式会社 侵害受容性疼痛の新規治療用医薬組成物
WO2010029959A1 (ja) 2008-09-11 2010-03-18 アステラス製薬株式会社 モルホリン誘導体の新規な塩

Also Published As

Publication number Publication date
BRPI0808806A2 (pt) 2014-08-19
KR20090130052A (ko) 2009-12-17
MX2009009701A (es) 2009-10-07
EP2123643A4 (en) 2011-12-07
US20100113451A1 (en) 2010-05-06
CA2680938A1 (en) 2008-09-18
RU2009138032A (ru) 2011-04-20
TW200846003A (en) 2008-12-01
AU2008225379A1 (en) 2008-09-18
JPWO2008111669A1 (ja) 2010-06-24
RU2465906C2 (ru) 2012-11-10
EP2123643A1 (en) 2009-11-25
JP5278308B2 (ja) 2013-09-04
IL200669A0 (en) 2010-05-17
US20130023535A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
WO2012005500A3 (ko) 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SG153830A1 (en) Galenic formulations of organic compounds
WO2004110498A3 (en) Drug conjugate composition
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2004034978A3 (en) Treating obesity with selective androgen receptor modulators
EP4378482A3 (en) Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
WO2006124447A3 (en) Substituted n-arylpyrrolidines as selective androgen receptor modulators
WO2006135536A3 (en) Papillary muscle attachement for left ventricular reduction
WO2004052847A3 (en) Tricyclic steroid hormone nuclear receptor modulators
WO2005030128A3 (en) Pyrazole modulators of metabotropic glutamate receptors
WO2005092392A3 (en) Conjugated psychotropic drugs and uses thereof
WO2005056524A3 (en) Therapeutic agents useful for treating pain
CN102202615A (zh) 男性用阴茎矫正装置
RU2012145116A (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольного жирового гепатоза и способ предупреждения или лечения неалкогольного жирового гепатоза с ее использованием
WO2004087048A3 (en) Benzamide modulators of metabotropic glutamate receptors
EP1889614A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2008111669A1 (ja) 糖尿病性神経障害の新規予防剤及び／又は治療剤
WO2008060332A3 (en) Methods for treating or reducing muscle fatigue
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
CA2262268C (en) Method of treating impotence due to spinal cord injury
WO2006071601A3 (en) Therapeutic compositions for intranasal administration of ketorolac
WO2007145863A3 (en) Sustained release formulation of naltrexone
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880008486.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08722106

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009504092

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008722106

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008225379

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200669

Country of ref document: IL

Ref document number: 12009501668

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009701

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2680938

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5434/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008225379

Country of ref document: AU

Date of ref document: 20080314

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20097021416

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009138032

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12530745

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0808806

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090911